Citation Tools
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
823 IMM20059, a novel anti-EPN1 antibody, in combination with atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 823 IMM20059, a novel anti-EPN1 antibody, in combination with atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy